Activity

Coterra Energy Reports First-Quarter 2023 Results, Announces Quarterly Dividend and Provides Update on Share Repurchase Program

Retrieved on: 
Jeudi, mai 4, 2023
Oil, Gas, Energy, Permian, Coterra, LOE, Activity, Share repurchase, Sustainability reporting, Natural gas, Anadarko Basin, G&A, GAAP, Financial Accounting Standards Board, Public expenditure, Atkinson Center for a Sustainable Future, Nature, Progress Energy Inc, Webcast, Free cash flow, Adjustment, NYSE, Bank, Clothing, Airline

Coterra Energy Inc. (NYSE: CTRA) (“Coterra” or the “Company”) today reported first-quarter 2023 financial and operating results.

Key Points: 
  • Coterra Energy Inc. (NYSE: CTRA) (“Coterra” or the “Company”) today reported first-quarter 2023 financial and operating results.
  • As we look ahead, Coterra will remain disciplined and focused on value creation through consistent, profitable growth.”
    Net Income (GAAP) totaled $677 million, or $0.88 per share.
  • As of March 31, 2023, Coterra had total long-term debt of $2.2 billion with a principal amount of $2.1 billion.
  • Coterra will host a conference call tomorrow, Friday, May 5, 2023, at 9:00 AM CT (10:00 AM ET), to discuss first-quarter 2023 financial and operating results.

International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

Retrieved on: 
Jeudi, mai 4, 2023
HKCEC, Diabetes, GBA, Public, National Administration of Traditional Chinese Medicine, Patient, R, Laboratory, Wellness, National government, Convention center, Noise, Tetraplegia, IHW, University, Research, Genetic distance, Government, USB On-The-Go, HKTDC, Hong Kong Trade Development Council Trade Fairs, Traditional Chinese medicine, AR, D, National Health Commission, International, Health, Brain Trauma Foundation, Hong Kong International Medical Devices and Supplies Fair, Health care, Stroke, Global Health, Rehabilitation, Climate change, Technopolis, Partnership, Activity, HKSAR, Republic, HKSTP, City, AI, Medtech, Summit, Management, Medical device, Pharmaceutical industry, Property management, Film industry, Medical imaging, Biotechnology

"The second IHW provides the perfect opportunity to bring together the world's elite in the medical, research and financial fields in Hong Kong," she added.

Key Points: 
  • "The second IHW provides the perfect opportunity to bring together the world's elite in the medical, research and financial fields in Hong Kong," she added.
  • "Our partnerships make this event very meaningful and highlights the importance of collaboration to drive forward the healthcare industry.
  • They will discuss the latest developments in public health, medical technology and healthcare investment and explore the future of the healthcare ecosystem and opportunities within it.
  • Also on day one, the InnoHealth Showcase and exhibition area at the HKCEC will feature more than 140 healthcare start-ups.

Tordrillo Mountain Lodge Announces Summer 2023 Highlights July Through September

Retrieved on: 
Mercredi, mai 3, 2023
Yoga, Dall sheep, Heart, De Havilland Canada DHC-3 Otter, National park, Salmon, Via ferrata, Lake Clark (Alaska), Triumvirate, Woman, Entomology, Trimble, Adventure, Southcentral Alaska, Massage, Activity, Gardening, School, Fly fishing, River, Prince, Otter, Fly, Safety, Talachulitna River, Lake, Amusement park, Tourism, Hotel, Tordrillo Mountains

ANCHORAGE, Alaska, May 3, 2023 /PRNewswire/ -- Tordrillo Mountain Lodge, Alaska's renowned heli-ski resort, today announced exclusive summer travel adventures for guests from July 7 through September 10 including snorkeling with salmon, an exclusive Fly Fishing 101 Weekend, women's adventure packages, children's activities, and private float plane trips to three national parks from the lodge's remote location on Judd Lake, located 60 miles from Anchorage.

Key Points: 
  • The luxury adventure lodge offers guests remote access to millions of acres of pristine mountain terrain.
  • With unrivaled access to millions of acres of pristine mountain terrain, Tordrillo Mountain Lodge offers summer activities for all levels of experience and ages.
  • Snorkel with salmon - Each summer, approximately 35,000 wild salmon swim nearly 100 miles up three different rivers before making their final push up the Talachulitna River to enter Judd Lake, located in front of Tordrillo Mountain Lodge.
  • Fly Fishing 101: New this summer, Tordrillo Mountain Lodge will offer an exclusive fly-fishing weekend experience from August 25-28, 2023.

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

Retrieved on: 
Mardi, mai 2, 2023
Abstract, Associate Director of National Intelligence and Chief Information Officer, Gene, Activity, Doctor of Philosophy, MPV, Los Angeles Convention Center, American Society of Gene and Cell Therapy, Translational medicine, Patient, Cell, ISCB Senior Scientist Award, Development, Poster, Society, Computational biology, Vaccine

PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio, will deliver an invited, oral presentation titled “CD 19 CAR T-cells for SLE” as part of the session titled “Immune Effector Cells: 2023 and Beyond!” on Tuesday, May 16, 2023, at 11:05 a.m. PT at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, which is being held at the Los Angeles Convention Center in Los Angeles, CA from May 16-20, 2023.

Key Points: 
  • PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio, will deliver an invited, oral presentation titled “CD 19 CAR T-cells for SLE” as part of the session titled “Immune Effector Cells: 2023 and Beyond!” on Tuesday, May 16, 2023, at 11:05 a.m. PT at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, which is being held at the Los Angeles Convention Center in Los Angeles, CA from May 16-20, 2023.
  • In addition, new preclinical data for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, and updated clinical and translational data from the ongoing DesCAARTes™ trial for DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) will be presented in poster presentations.
  • Details of the poster presentations are as follows:
    Title: Preclinical Specificity and Activity of CABA-201, a Fully Human 4-1BB Containing CD19 CAR T Therapy for Treatment-Resistant Autoimmune Disease
    Presenter: Jinmin Lee, Ph.D., Associate Director, Preclinical Research and Jason Peng, Ph.D., Senior Scientist at Cabaletta Bio
    Presenter: Jenell Volkov, Ph.D., Director, Translational Medicine and Daniel Nunez, Ph.D., Associate Director, Computational Biology at Cabaletta Bio
    Additional information, including the accepted abstracts, can be accessed on the ASGCT website .
  • Presentation materials will be made available on the Posters & Publications section of the Company’s website following the event.

BeyondTrust Expands Identity & Access Security Platform with New Features and Advanced Capabilities

Retrieved on: 
Mardi, mai 2, 2023
Cloud, Blue Prism, Database, RPA, Partnership, Hardware security module, Activity, ECS, Policy, Robotic process automation, GCP, Elevation, HSM, TAP, Microsoft, UiPath, Entrust, Computer, Creativity, Organization, Passwordless authentication, Trust, Privilege Management Infrastructure, Access, Jamf, Hardware, Azure, Mac, AWS, Dimension, BeyondTrust, Video game, Risk management, Mobile phone, Medical device, Online shopping, Computer data storage, Dynamo, Thales of Miletus, SIEM

Privileged Remote Access 23.1 brought to market new Infrastructure Access Management functionality enabling developers, cloud ops engineers, and technical workers to securely and more easily access critical business resources.

Key Points: 
  • Privileged Remote Access 23.1 brought to market new Infrastructure Access Management functionality enabling developers, cloud ops engineers, and technical workers to securely and more easily access critical business resources.
  • This release includes:
    Streamlined Access Console – Grants developers and cloud ops engineers exclusive access to authorized systems, fostering productivity and focus.
  • These new features enhance productivity for technical workers and provide admins with greater control of secure access to their systems.
  • We continue to invest in innovation to enable visibility and control of all identities and access pathways, detect advanced identity threats, and automatically remediate gaps and adjust policies," said Marc Maiffret, Chief Technology Officer, BeyondTrust.

NordPass introduces improvements to its business suite

Retrieved on: 
Jeudi, avril 13, 2023
Chrome, Organization, Activity, News, Firefox, Mobile phone, Online shopping, NordPass

This news follows the company’s recent announcements of introducing 2FA functionality within the NordPass app and launching passkeys support.

Key Points: 
  • This news follows the company’s recent announcements of introducing 2FA functionality within the NordPass app and launching passkeys support.
  • With the Activity Log filtering, business users will be able to easily narrow down actions performed by organization members.
  • In the Business Admin Panel, people granted “Owner” or “Admin” rights will now be given the option to filter the massive feed of activity logs by date and member on NordPass.
  • 11,528,130), NordPass made it available on the mobile app for all NordPass Business accounts.

Fair Trade USA™ Factory Production Standards 2.0 Transformation

Retrieved on: 
Jeudi, mars 16, 2023
Ruff, Beauty, Fair Trade USA, Fair Labor Association, Certification, Education, FLA, Fair trade certification, Cosmetics, E.l.f. (cosmetics), Product category volume, Third party, Language, Activity, Fair trade, Renewable energy, Video game

OAKLAND, Calif., March 16, 2023 /PRNewswire/ -- Fair Trade USA™ recently unveiled its new Factory Production Standard, significantly improving its overall certification process. The redesign supports accelerated factory onboarding, expansion into new product category and countries, affordability, and accessibility.

Key Points: 
  • OAKLAND, Calif., March 16, 2023 /PRNewswire/ -- Fair Trade USA™ recently unveiled its new Factory Production Standard , significantly improving its overall certification process.
  • We envision a time when sourcing from Fair Trade Certified factories is the norm, and all consumers have access to Fair Trade Certified products."
  • "We applaud Fair Trade USA's efforts to streamline certification under their Factory Redesign Program with the ultimate goal of increasing funds available to workers.
  • "It's been very meaningful to partner with Fair Trade USA to establish the first Fair Trade Certification in the beauty industry.

Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)

Retrieved on: 
Jeudi, mars 16, 2023
Weight gain, Quality of life, Phenotype, Brain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Hippocampus, Dendrite, DSM-IV codes, MDD, Bioequivalence, SSRI, Cognitive deficit, Neurogenesis, Depression, Grammatical mood, Tablet, Tonix Pharmaceuticals, FDA, IR, Neuroplasticity, Incidence, Safety, Activity, Neuron, ER1, Food, Suicide, New chemical entity, Pharmaceutical industry, Generic drug, CA3

The double-blind, placebo-controlled registrational-quality study has a target enrollment of 300 participants at approximately 30 sites across the U.S.

Key Points: 
  • The double-blind, placebo-controlled registrational-quality study has a target enrollment of 300 participants at approximately 30 sites across the U.S.
  • Results from a planned interim analysis are expected to be released in the fourth quarter of 2023.
  • The proprietary once-daily formulation of TNX-601 ER was designed to be bioequivalent to the three-times-a-day formulation of tianeptine sodium (amorphous) immediate release (IR) tablets.
  • Extensive animal studies have taught us that tianeptine restores the stress-induced deficits in neuroplasticity and neurogenesis.

Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting

Retrieved on: 
Mardi, mars 14, 2023
AACR, Annual general meeting, Abstract, KNTE, American Association for Cancer Research, SAN, BRAF, Patient, NRAS, High, MEK, Activity, Safety, Clinical trial, Cancer, Pharmaceutical industry

The oral presentation represents the first report of safety and clinical efficacy data from the monotherapy dose escalation portion of KN-8701, an ongoing global Phase 1 clinical trial evaluating exarafenib in patients with BRAF-altered solid tumors and NRAS mutant-positive melanoma.

Key Points: 
  • The oral presentation represents the first report of safety and clinical efficacy data from the monotherapy dose escalation portion of KN-8701, an ongoing global Phase 1 clinical trial evaluating exarafenib in patients with BRAF-altered solid tumors and NRAS mutant-positive melanoma.
  • ET, at which time Kinnate will also make the abstract available under the Presentations and Publications section of Kinnate.com .
  • The company intends to present an updated data cut with additional patients and follow-up during the oral presentation on April 17.
  • Title: Exarafenib (KIN-2787) is a Potent, Selective Pan-RAF Inhibitor with Activity in Preclinical Models of BRAF Class II/III Mutant and NRAS Mutant Melanoma

Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure

Retrieved on: 
Mardi, février 28, 2023
Windtree Therapeutics, Metabolite, Therapy, Arrhythmia, Journal of Pharmacology and Experimental Therapeutics, CMO, Istaroxime, Acute decompensated heart failure, Treatment, Journal, Heart failure, Probability, Activity, Relaxation, Human, Calcium, Public health genomics, Cardiogenic shock, Experiment, Pharmaceutical industry, Medical device, Pharmacology

The publication emphasizes the interest in SERCA2a as a target in treating heart failure because it is instrumental in calcium management, critically important in heart muscle contraction and relaxation.

Key Points: 
  • The publication emphasizes the interest in SERCA2a as a target in treating heart failure because it is instrumental in calcium management, critically important in heart muscle contraction and relaxation.
  • Our SERCA2a activators uniquely interfere with phospholamban, a protein that inhibits SERCA2a function and does so excessively in heart failure.
  • The preclinical data discussed in the paper provides rationale for selective targeting of SERCA2A in the treatment of heart failure.
  • “Windtree’s SERCA2a activator drug candidates could represent a promising IV or oral approach to treat heart failure,” said Steve Simonson, CMO of Windtree Therapeutics.